Stock Prices Updates, Study Results, Financial Results, and Share Repurchase Program - Analyst Notes on Gilead, Pfizer, Pharmacyclics, Intuitive Surgical and Mallinckrodt

NEW YORK, May 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc (NYSE: PFE), Pharmacyclics Inc. (NYSE: PCYC), Intuitive Surgical, Inc. (NASDAQ: ISRG) and Mallinckrodt plc (NYSE: MNK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2140-100free.

--
Gilead Sciences Inc. Analyst Notes
On May 2, 2014, the shares of Gilead Sciences Inc. (Gilead) snapped the four-day long winning streak and fell 1.66% to end the day at $77.71. During the session, the Company's shares opened at $79.30 and fluctuated in the range of $76.65 - $79.50, with the total of 16.78 million shares changing hands. The stock has risen 8.53% upto May 2, 2014 since the closing on April 21, 2014, a day prior to the financial results announcement. The Company released its Q1 2014 financial results on April 22, 2014, showing that the net income jumped over three-fold on back of robust sales growth. Gilead's net income increased to $2.3 billion in Q1 2014 from $722.2 million in Q1 2013. Over the past 12 months, the shares of Gilead increased 40.90%, as compared to the NASDAQ Composite, which increased 22.05% during the same period. The full analyst notes on Gilead are available to download free of charge at:

http://www.analystsreview.com/2140-GILD-07May2014.pdf

--
Pfizer Inc Analyst Notes
On May 1, 2014, Pfizer Inc. (Pfizer) announced results from the three pivotal studies of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules). The Company informed that one of the studies demonstrated significant difference in pain scores in patients with moderate-to-severe chronic low back pain receiving ALO-02 as compared to placebo; while the other studies showed lower abuse potential of ALO-02 in recreational opioid users by oral and intranasal routes when compared to immediate-release oxycodone. Data from these three studies were presented at the 33rd Annual Meeting of the American Pain Society (APS) in Tampa, Florida. Dr. Steven Romano, Senior Vice President and Head, Medicines Development Group, Pfizer Global Innovative Pharmaceutical Business, commented, "These study results point to the potential of ALO-02 as an important treatment option, for appropriate patients, with abuse-deterrent features." The full analyst notes on Pfizer are available to download free of charge at:

http://www.analystsreview.com/2140-PFE-07May2014.pdf

--
Pharmacyclics Inc. Analyst Notes
On May 2, 2014, Pharmacyclics Inc. (Pharmacyclics) announced financial results for Q1 2014. Pharmacyclics reported total revenue of $119.4 million versus $2.8 million in the year-ago period, helped mainly by sales of Imbruvica (ibrutinib) and milestone revenue recognized during the quarter. Imbruvica, which was approved by U.S. Food and Drug Administration in November 2013, generated sales of $56.2 million in Q1 2014. For Q1 2014, net income came in at $18.3 million, or $0.23 per diluted share versus net loss of $51.9 million or $0.73 per diluted share in Q1 2013. The Company surpassed the Zacks consensus earnings estimate by 9 cents. Despite better-than-expected Q1 2014 numbers, shares of the Company tanked 7.44% on the same day which, according to Zacks, was due to disappointing full-year 2014 revenue guidance. The Company expects full-year 2014 net product revenues to be $295 million, plus or minus 5%. The full analyst notes on Pharmacyclics are available to download free of charge at:

http://www.analystsreview.com/2140-PCYC-07May2014.pdf

--
Intuitive Surgical, Inc. Analyst Notes
On May 2, 2014, Intuitive Surgical, Inc. (Intuitive Surgical) announced that it has entered into an accelerated share repurchase program (ASR Program) with Goldman, Sachs & Co., (Goldman) under which Intuitive Surgical will repurchase $1 billion of its common stock from Goldman. The Company expects that a majority of the shares repurchased under the ASR Program will be received and retired within two weeks. The Company informed that it had $1 billion remaining under Board authorized repurchases before entering into the ASR Program. The Company expects to fund the ASR Program through cash and investments. Dr. Gary S. Guthart, President and CEO of Intuitive Surgical, commented, "Our decision to repurchase $1 billion in Intuitive Surgical stock on an accelerated basis reflects our long-term view of the value our company can bring to patients, surgeons and hospitals." The full analyst notes on Intuitive Surgical are available to download free of charge at:

http://www.analystsreview.com/2140-ISRG-07May2014.pdf

--
Mallinckrodt plc Analyst Notes
On May 2, 2014, the shares of Mallinckrodt plc (Mallinckrodt) gained 4.60%, ending the day at $73.84. During the session, the Company's shares opened at $70.59 and oscillated in the range of $69.89 - $75.12. Mallinckrodt traded 3.49 million shares during the day, higher than its 30-day average trading volume of 3.17 million shares. Over the past 12 months, the shares of the Company increased 64.09%, outperforming the S&P 500, which increased 14.76% during the same period. The full analyst notes on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/2140-MNK-07May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review